Piper Sandler maintains Caris Life Sciences at Neutral, raises price target to $25 from $22
Piper Sandler kept its Neutral rating on Caris Life Sciences but raised its price target to $25 from $22, suggesting a 2.2% downside from the last close. Other recent analyst targets for the company range from $30 to $38.
How this was made

The 30-second read
Why it matters
Analyst target increase may prompt short-term buying pressure.
Market read
Analyst target change provides modest trading signal.
What to watch
No new clinical data; price move relies solely on analyst opinion.
Background
Caris Life Sciences is a biotech firm focused on cancer diagnostics.
Market effects
May lift sentiment in the biotech sector.
Limited to US biotech investors.
Low
Counterpoint
Target raise could be premature if upcoming trial data disappoints.
Key entities
- analystPiper Sandler
Equity research firm issuing the target raise.

